611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...

Medical Disorders
Basic InformationLookupsLatest News
Pandemic Is Devastating Low-Income Black HouseholdsObesity Ups Women's Odds for Early Hip FractureFootball-Loving States Drop The Ball on Concussion: StudyCOVID Can Harm the Infant HeartCDC Director Warns of Dire Winter Ahead for COVID Hospitalizations, DeathsRelief for America's Unemployed Could Be Crucial for HealthMany Hospitalized COVID Patients Will Need Longer-Term Care at HomeCDC Shrinks COVID Quarantine Time, Advises Against Holiday TravelShould Cancer Survivors Be Prioritized for COVID Vaccine?Take Care of Your Mental Health During PandemicGay, Lesbian Adults Often Miss Out on Cholesterol MedsBritain Approves Emergency Use of Pfizer's COVID VaccineHealth Care Workers, Nursing Home Residents to Get First Vaccines: PanelNeed an IV or Stitches? Virtual Reality or Hypnosis Might Ease PainCOVID-19 Can Damage Lungs So Badly That 'Only Hope' is TransplantPandemic Could Be Golden Time for Narcissists: Study'Smell Training' Might Speed the Sense's Return After COVIDEye Injury Reported From Germ-Killing UV LampsCOVID Hospitalizations in U.S. Hit Record High'Repeat After Me' for Better Diabetes CareVentilators May Leave COVID Survivors With Windpipe InjuriesLockdown Loneliness Could Worsen Parkinson's SymptomsDiabetes, High Blood Pressure Raise Odds of COVID Harming BrainCOVID in Kids: The Most Telling SymptomsFauci Warns of Another Surge of COVID Cases After Thanksgiving TravelWood-Fired Cooking a Cause of Lung Illness in Developing WorldDelirium May Be Only Sign of Severe COVID in Elderly: StudySimple Move May Boost Spinal Fusion OutcomesCould the TB Vaccine Help Prevent COVID-19?When COVID Strikes Cancer Patients, Men Fare WorseMost Americans Over 50 Would Get COVID Vaccine: PollAnother Study Casts Doubt on 'Convalescent Plasma' as COVID-19 TreatmentCOVID Vaccine Rollout Could Begin Mid-December, Fauci SaysFauci: 'People Should Feel Confident' New COVID Vaccines Safe, EffectiveCould the Pill Reduce Asthma Attacks?Coronavirus Most Contagious Soon After InfectionPeople Should Know That COVID Vaccine Might Spur Transient Sickness: CDC ExpertsAnother Study Finds COVID Usually Mild in KidsBlacks, Hispanics Account for More Than Half of COVID Deaths: StudyCollege Kid Coming Home for Thanksgiving? Here's How to Keep Your Family SafeParents' Age Key to Whether Kids Get Vaccinated Against COVID, Study FindsVegan Diets Tied to Higher Bone Fracture RiskThird COVID Vaccine Shows Effectiveness; FDA Approves New TreatmentWhich Kids With COVID Will Get Very Sick?Add Kids to COVID Vaccine Trials, Pediatricians' Group SaysLosing Your Hair Because of Pandemic Stress?How Hospitals Can Cut Patients' FallsMany Young Americans Lonely, Depressed During Pandemic: SurveyWHO Says No to Remdesivir as COVID-19 TreatmentBirx Says U.S. COVID Cases Are Skyrocketing as Holidays Approach
Questions and AnswersLinksBook Reviews
Related Topics

Men's Health
Women's Health

Newer Rheumatoid Arthritis Drug May Help Ease Tough-to-Treat Cases

HealthDay News
by By Dennis Thompson
HealthDay Reporter
Updated: Oct 19th 2020

new article illustration

MONDAY, Oct. 19, 2020 (HealthDay News) -- A recently approved rheumatoid arthritis medication appears to be an effective second-line therapy when biologic treatments start to fail, a new clinical trial reports.

Arthritis sufferers treated with upadacitinib had a significantly greater reduction in their symptoms and disease activity than people treated with a standard disease-modifying antirheumatic drug (DMARD), said co-researcher Dr. Aileen Pangan. She is executive medical director of immunology clinical development for the pharmaceutical company AbbVie in North Chicago, Ill.

The drug, marketed under the brand name Rinvoq, also helped twice as many patients enter remission from their rheumatoid arthritis, according to a report in the Oct. 15 issue of the New England Journal of Medicine.

"Upadacitinib has shown superiority to one of the current standard-of-care treatment options in the clinic for these difficult-to-treat patients," Pangan said. "It is important for physicians to have multiple treatment options available, including medications with different mechanisms of action, to help provide patients with the treatment that is right for them."

Rinvoq received U.S. Food and Drug Administration approval in August 2019 for treatment of moderate to severe rheumatoid arthritis.

This 24-week clinical trial aimed to assess Rinvoq's effectiveness in helping rheumatoid arthritis patients for whom DMARD treatment had failed.

More than 600 patients were recruited for the trial. All were suffering swollen or tender joints even though they were being treated with at least one biologic DMARD, or they had unacceptable side effects from a DMARD.

Half were treated with Rinvoq, and half were treated with a standard biologic DMARD called abatacept (Orencia).

DMARDs act upon the immune system in different ways to reduce joint inflammation.

Rinvoq belongs in a class of drugs called Janus kinase (JAK) inhibitors, which also treat rheumatoid arthritis symptoms by manipulating the immune system, Pangan said.

"Janus kinase enzymes play a critical role in the body by transmitting messages from the outside to the inside of cells," she said. "In the immune system, a malfunction can lead to the generation of autoimmune inflammatory diseases. In the immune cells of patients with rheumatoid arthritis, JAK enzymes transmit signals that lead to the inappropriate activation of the immune system to attack and cause inflammation in the joints."

About 30% of patients treated with Rinvoq went into remission, compared with about 13% of the Orencia patients, the researchers reported.

The results are strong enough to "help push JAK inhibitors to the forefront of treatment for rheumatoid arthritis," according to an editorial by two University of Oslo rheumatologists, which accompanied the clinical trial results.

However, the editorial added that "in order to compete in the crowded field of targeted treatments for rheumatoid arthritis, JAK inhibitors not only have to prove that they are efficacious and safe -- they also need to be less expensive than or clinically superior to biologic DMARDs."

Based on this and other trials, editorialists Dr. Guro Goll and Dr. Tore Kvien noted that there appears to be a risk of blood clots in people taking JAK inhibitors.

One person on Rinvoq suffered a nonfatal stroke in this trial, and there also was one case each of deep-vein thrombosis and pulmonary embolism in those taking the drug, the results showed. One patient in the Rinvoq group died from cardiac arrest suffered while in the hospital with pneumonia.

"Our understanding of JAK inhibitors, particularly regarding the risk of thromboembolic events, is evolving," Goll and Kvien added. "A 24-week trial may be too short to detect meaningful long-term efficacy and safety."

The new drug isn't cheap, either, costing around $60,000 a year, according to the website pharmaphorum.

More information

The U.S. Centers for Disease Control and Prevention has more about rheumatoid arthritis.